- Market Capitalization, $K 85,556
- Shares Outstanding, K 16,082
- Annual Sales, $ 5,410 K
- Annual Income, $ -5,330 K
- 60-Month Beta 0.73
- Price/Sales 2.79
- Price/Cash Flow N/A
- Price/Book 4.50
|Period||Period Low||Period High||Performance|
| || |
-0.86 (-13.92%)since 01/21/20
| || |
-0.78 (-12.79%)since 11/21/19
| || |
-0.98 (-15.56%)since 02/21/19
AVEO Oncology (NASDAQ: AVEO) today announced that it will effect a 1-for-10 reverse stock split of its common stock that will be effective as of 5:00 p.m. Eastern Time today, February 19, 2020. AVEO's...
AVEO Oncology (NASDAQ: AVEO) today announced the publication of results from a monotherapy trial of tivozanib, the Company's vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI),...
AVEO releases results from a phase Ib study on ficlatuzumab in combination with nab-paclitaxel and gemcitabine for treating advanced pancreatic cancer. Shares inch up.
AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the presentation of results from an investigator-sponsored Phase 1b trial of ficlatuzumab, AVEO's potent hepatocyte growth factor (HGF) inhibitory...
AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Erick Lucera as chief financial officer. Mr. Lucera will be responsible for managing all aspects of the Company's financial and accounting...
Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.
AVEO (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AVEO Oncology (NASDAQ: AVEO) today announced that previously reported data from its Phase 3 TIVO-3 study were published in The Lancet Oncology. TIVO-3 is the Company's Phase 3 randomized, controlled, multi-center,...
AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 31st Annual Piper Jaffray Healthcare Conference in New York on Tuesday, December...
AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Scarlett Spring to its Board of Directors. Ms. Spring brings to AVEO extensive sales, commercial, and leadership experience in the biopharmaceutical...